

CHINA PHARMA HOLDINGS, INC.
Form 8-K
December 13, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 8, 2016

CHINA PHARMA HOLDINGS, INC.

(Exact name of Registrant as specified in charter)

<u>Nevada</u>	<u>001-34471</u>	73-1564807
(State or other jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China 570216
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: +86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

On December 8, 2016, China Pharma Holdings, Inc. (the "Company") held its annual shareholders meeting for the fiscal year ended December 31, 2015 (the "Annual Meeting"). Holders of 27,271,585 shares of the Company's common stock were present in person or by proxy at the Annual Meeting, representing 62.6% of the total outstanding shares of common stock and therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Annual Meeting as of the record date.

The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows. No broker non-votes were counted for any of the proposals as the Company chose to.

1. A proposal to elect three independent director nominees to our Board of Directors to serve until the next annual meeting and until their successors are elected and qualified:

Director's Name	Votes For	Votes Withheld
Gene Michael Bennett	24,790,576	2,481,009
Yingwen Zhang	24,789,576	2,482,009
Baowen Dong	24,789,576	2,482,009

2. A proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officer as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.

For	Against	Abstain
24,895,511	2,347,574	58,500

3. A proposal to approve, on a non-binding, advisory basis, the frequency of the advisory vote on executive compensation:

One Year	Two Years	Three Years	Abstain
7,698,383	11,445	19,558,977	2,780

Pursuant to the foregoing votes, Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as independent directors; the compensation of registrant's named executive officers was approved; and the frequency of the advisory vote on executive compensation was decided to be once every three years.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 13, 2016

CHINA PHARMA HOLDINGS, INC.

By: /s/ Zhilin Li

Name: Zhilin Li

Title: President and Chief Executive Officer